Key Takeaways:
Zealand Pharma's obesity pipeline faces a make-or-break moment as investors shift focus from survodutide's tolerability woes to petrelintide's amylin promise.
Zealand Pharma's survodutide posted 16.6% weight loss in a mid-stage trial but saw 19% of patients drop out due to side effects, a discontinuation rate roughly five times that of Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
"The tolerability data looks highly disappointing and will likely significantly limit its usage," UBS analysts wrote in a research note, slashing survodutide peak sales estimates by nearly 80% and cutting their price target on the stock to 540 Danish kroner from 730 kroner.
The placebo-adjusted discontinuation rate due to adverse events stood at 18.8%, versus roughly 4% for the leading GLP-1 therapies, according to Jefferies. The data landed alongside Lilly's presentation of retatrutide, a triple-hormone agonist that showed no efficacy plateau through 104 weeks — creating what RBC analysts described as potentially the most efficacious obesity therapy in development.
The Copenhagen-listed stock has lost 38% year-to-date, including its two worst trading days on record since the company went public in 2010. Investors are now betting on petrelintide, Zealand's amylin-based drug partnered with Roche, which is due to initiate late-stage trials in the second half of 2026 and report mid-stage results in diabetes patients.
Survodutide's Tolerability Gap Reshapes the Calculus
Survodutide, a GLP-1/glucagon dual agonist that Zealand licensed to Boehringer Ingelheim, met its primary efficacy endpoint but the dropout rate overshadowed the result. UBS maintained a Buy rating on the stock but said survodutide's commercial opportunity is now primarily tied to metabolic dysfunction-associated steatohepatitis, or MASH, rather than obesity.
The tolerability gap matters because investors increasingly compare obesity drugs not just on weight loss but on how many patients can actually stay on therapy. Jefferies analysts noted the data puts additional downside risk on shares and raises the importance of future trials assessing survodutide's benefit for liver patients. Several analysts, including Jefferies and UBS, pointed to 2027 as the earliest inflection point for Zealand.
Petrelintide Carries the Obesity Narrative
Amylin, like GLP-1, is a natural hormone that regulates blood sugar and appetite, but is produced in the pancreas rather than the gut. Zealand CEO Adam Steensberg described petrelintide's profile as a "sweet spot" between double-digit weight loss and placebo-like tolerability, speaking at the American Diabetes Association's Scientific Sessions in New Orleans earlier this month.
"I truly believe that when these amylin drugs launch, we can have that, what I've described as an iPhone moment, because patients are so aware of the experience they have on the GLP-1s," Steensberg said.
The amylin class has become a focal point for the industry, with Eli Lilly developing eloralintide and other players entering the space. UBS said the size of the consumer obesity market will likely allow multiple players, even as Novo Nordisk and Lilly remain strongly positioned in both current and future markets.
Jyske Bank analyst Henrik Hallengreen Laustsen said Zealand needs to differentiate petrelintide from other amylin products. "My overall take away from ADA across the company presentations was the increased focus on side-effects and differentiation from current best-in-class products," he said.
Zealand had 1.2 billion Danish kroner in cash as of its most recent filing, providing runway through key petrelintide readouts. The stock's recovery hinges on whether petrelintide can deliver the tolerability profile that survodutide could not — and whether that is enough to compete in a market increasingly dominated by Lilly's triple-agonist franchise.
This article is for informational purposes only and does not constitute investment advice.
